Home / Stocks / Anlon Healthcare Limited
AHCL

Anlon Healthcare Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹24.97

Change

-0.48 (-1.89%)

Open

₹25.33

Prev. Close

₹25.45

Day High

₹25.77

Day Low

₹24.8

Volume Analysis

Traded

2,077,848

Delivered

1,128,517

Delivery %

54.31%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (24.0%)

Weaknesses (0)

No signal for this stock

Opportunities (3)

  • •Strong 3-year EPS growth (53.3%)
  • •Strong 3-year revenue growth (15.0%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹26.53 ₹26.15 ₹25.56 ₹25.18 ₹24.59 ₹24.21 ₹23.62
Fibonacci ₹26.15 ₹25.78 ₹25.55 ₹25.18 ₹24.81 ₹24.58 ₹24.21
Camarilla ₹25.24 ₹25.15 ₹25.06 ₹25.18 ₹24.88 ₹24.79 ₹24.7

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-83.16%

1 Week

-6.58%

1 Month

-2.58%

3 Months

+74.86%

6 Months

+79.51%

1 Year

-84.03%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹5.11

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

47.58%

Net margin 15.0% × asset turnover 0.52x × equity multiplier 6.1x

Company Overview

Sector

Healthcare

Market Cap

₹1,348 Cr

P/E (TTM)

37.8

ROE

18.4%

Book Value

₹4.84

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Anlon Healthcare Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 54/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (24.0%). Strong 3-year EPS growth (53.3%).

TopFund Score — Fundamentals Quality

54/100 — Average

Data confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

91

Valuation

26

Cash Flow

0

Corporate Governance

56

Momentum

55

Institutional Ownership

31

Business Quality

65

Risk & Volatility

16

Liquidity

46

From Screener.in

  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company might be capitalizing the interest cost
  • −Company has high debtors of 220 days.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

We have attached herewith earning call transcript for the H1/Q2 FY-27. Kindly take the same on your record. Thank you.

Q2 FY27 earnings call audio recording uploaded on November 3, 2026.

We have attached herewith copy of newspaper publication. Kindly take the same on your record. Thank you.

We have attached herewith Investor Presentation as per Regulation 30 of SEBI (LODR) Regulation, 2015. Kindly take the same on your record. Thank you.

Board approved Q2 and H1 FY2026 standalone and consolidated results on October 29, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2024 (S) Sep 2024 (S) Dec 2024 (S) Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 38 24 9 49 33 52 36 51 88 106
Expenses + 31 17 9 32 27 38 23 36 72 80
Operating Profit 7 8 1 17 6 14 12 15 16 25
OPM % 18.0% 31.0% 6.0% 35.0% 19.0% 26.0% 35.0% 30.0% 18.0% 24.0%
Other Income + 0 0 0 0 0 0 0 0 0 0
Interest 1 1 1 1 1 1 2 1 1 1
Depreciation 0 0 0 1 0 0 0 0 1 1
Profit before tax 5 6 0 15 5 12 11 14 14 23
Tax % 17.0% 58.0% 759.0% -7.0% 29.0% 25.0% 51.0% 23.0% 39.0% 27.0%
Net Profit + 5 3 -2 17 4 9 5 11 8 17
EPS in Rs 0 0 0 0 0 0 0 0 0 0
Raw PDF — — — — — — — — — —
YoY Sales growth — — — — — — — 4 163 102

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 Mar 2026 TTM
Sales + 16 57 113 66 120 172 280
Expenses + 21 52 100 51 88 124 211
Operating Profit -5 6 13 16 32 48 68
OPM % -32.0% 10.0% 11.0% 24.0% 27.0% 28.0% 24.0%
Other Income + 0 0 0 0 0 0 0
Interest 3 4 4 4 4 4 4
Depreciation 2 2 2 2 2 2 3
Profit before tax -10 0 7 10 27 43 62
Tax % 3.0% 0.0% 17.0% 1.0% 24.0% 32.0% —
Net Profit + -10 0 6 10 21 29 42
EPS in Rs 0 0 0 0 1 1 1
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth — 258 97 -41 — 43 —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 Mar 2026 Sep 2026
Reserves -10 -10 -5 5 41 177 151
Borrowings + 54 62 70 81 67 44 72
Other Liabilities + 16 21 34 26 34 100 123
Total Liabilities 71 85 112 128 181 374 453
Fixed Assets + 29 27 26 27 23 58 79
CWIP 0 0 0 0 0 0 1
Investments 0 2 4 1 1 1 1
Other Assets + 43 56 82 100 158 315 371
Total Assets 71 85 112 128 181 374 453
Equity Capital 12 12 12 16 40 53 106

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 Mar 2026
Cash from Operating Activity + -15 -2 -3 -3 -22 -59
Cash from Investing Activity + -2 0 0 -3 2 -36
Cash from Financing Activity + 16 3 2 8 19 118
Net Cash Flow -2 1 -1 2 -1 23
Free Cash Flow -15 -2 -3 -7 -19 -95
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 291 -32 -23 -21 -85 -114

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 52.68% → 52.68%
  Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 44.49% 42.6% 42.4% 44.43% 46.02%
Promoters 52.68% 52.68% 52.68% 52.68% 52.68%
FII 0.0% 0.23% 0.32% 1.67% 0.99%
DII 2.83% 4.49% 4.6% 1.23% 0.3%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Anlon Healthcare Limited (this stock) 1,348 37.8 5.25 18.4%
Fermenta Biotech Ltd. 1,367 29.4 3.27 17.3%
Shalby Limited 1,317 33.6 1.29 2.45%
Jagsonpal Pharmaceuticals 1,402 — 5.82 —
Kopran Ltd 1,281 32.6 2.44 4.91%
Gujarat Kidney N Sup Sp L 1,269 66.8 4.82 11.1%
Amrutajan Health Ltd 1,461 71.7 13.58 20.0%

Which Mutual Funds Hold Anlon Healthcare Limited?

Frequently Asked Questions about Anlon Healthcare Limited

Community Sentiment

What are other investors saying about Anlon Healthcare Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.